Diamedica Therapeutics to Resume Stroke Treatment Trials After FDA Removes Hold

By Adriano Marchese

Diamedica Therapeutics is preparing to resume trials for an acute ischemic stroke treatment after the U.S. Food and Drug Administration removed a hold on the drug candidate's application.

The clinical-stage biopharmaceutical company said the FDA removed the clinical hold placed on the investigational new drug application for ReMEDy2 phase 2/3 clinical trials studying DM199, a synthetic formulation of the human tissue-1 kallikrein protein which primarily aims to enhance collateral blood flow in brain tissues affected by a stroke.

Diamedica said preparations are now underway to resume the trials of DM199 as soon as possible.

Write to Adriano Marchese at [e-mail]

(END) Dow Jones Newswires

06-21-23 0854ET